Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

• Salvatore Siena,
• Kanwal Raghav,
• Toshiki Masuishi,
• Kensei Yamaguchi,
• Tomohiro Nishina,
• Elena Elez,
• Javier Rodriguez,
• Ian Chau,
• Maria Di Bartolomeo,
• Hisato Kawakami,
• Fumitaka Suto,
• Makito Koga,
• Koichiro Inaki,
• Yusuke Kuwahara,
• Issey Takehara,
• Daniel Barrios,
• Kojiro Kobayashi,
• Axel Grothey,
• Takayuki Yoshino

Affiliations

Salvatore Siena

Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda

Kanwal Raghav

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center

Toshiki Masuishi

Department of Clinical Oncology, Aichi Cancer Center Hospital

Kensei Yamaguchi

The Cancer Institute Hospital of JFCR

Tomohiro Nishina

National Hospital Organization Shikoku Cancer Center

Elena Elez

Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona

Javier Rodriguez

Medical Oncology Department, Clinica Universidad de Navarra

Ian Chau

Royal Marsden NHS Foundation Trust

Maria Di Bartolomeo

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori

Hisato Kawakami

Kindai University Hospital

Fumitaka Suto

Daiichi Sankyo

Makito Koga

Daiichi Sankyo, Co., Ltd

Koichiro Inaki

Daiichi Sankyo, Co., Ltd

Yusuke Kuwahara

Daiichi Sankyo

Issey Takehara

Daiichi Sankyo, Co., Ltd

Daniel Barrios

Daiichi Sankyo

Kojiro Kobayashi

Daiichi Sankyo

Axel Grothey

West Cancer Center

Takayuki Yoshino

National Cancer Center Hospital East